CLINICAL EFFICACY OF CANCER SUBCUTANEOUS IMMUNOTHERAPY WITH INTERLEUKIN-2 IN RELATION TO THE PRETREATMENT LEVELS OF TUMOR-GROWTH FACTOR INSULIN-LIKE GROWTH-FACTOR-I